Immunology
The Immunology Department at St James’s hospital runs a number of both investigator-led and industry centered drug trials in Immunology.
Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
---|---|---|---|---|
HAE Survey | Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregivers | Observational-non invasive | Takeda | Commercial: Industry |
EU-COVAT-2 BOOSTAVAC | An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4 th homologous mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2 | Clinical trial (2021-004889-35) | EU Horizon 2020 | Non-commercial: Academic |
HyQvia | Non-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQvia | Observational-non invasive (NCT01034969) | Baxalta | Commercial: Industry |
IOS registry | Icatibant Outcome Survey (IOS) registry protocol | Observational-non invasive (NCT01034969) | Shire | Commercial: Industry |
ABT in Urticaria | Health through attention based training (ABT) for patients in SJH with urticaria | Observational-non invasive | Non-commercial: Academic | |
Santorini | Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI) | Observational-non invasive | Daiichi Sankyo Europe GmbH | Commercial: Industry |
Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
---|---|---|---|---|
CDZ OLE | An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02859727)(2016-000468-41) | Novartis | Commercial: Industry |
CDZ | An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02435173) (2014-003876-22) | Novartis | Commercial: Industry |